SMFG
XBI icon

Sumitomo Mitsui Financial Group’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Sumitomo Mitsui Financial Group’s Portfolio XBI Stock Details XBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.32M Sell
8,359
-1,249
-13% -$169K 0.03% 91
2026
Q1 		$1.23M Buy
9,608
+184
+2% +$23K 0.02% 90
2025
Q4 		$64.4M Sell
9,424
-1,978
-17% -$227K 1.14% 15
2025
Q3 		$1.14M Sell
11,402
-908
-7% -$81.8K 0.02% 87
2025
Q2 		$1.02M Buy
12,310
+681
+6% +$54.3K 0.02% 88
2025
Q1 		$943K Sell
11,629
-79
-0.7% -$7.06K 0.02% 90
2024
Q4 		$1.05M Sell
11,708
-577
-5% -$55.9K 0.01% 91
2024
Q3 		$1.21M Sell
12,285
-971
-7% -$95.4K 0.03% 88
2024
Q2 		$1.23M Sell
13,256
-843
-6% -$75.6K 0.04% 88
2024
Q1 		$1.34M Sell
14,099
-1,111
-7% -$103K 0.04% 89
2023
Q4 		$1.36M Sell
15,210
-8,252
-35% -$613K 0.04% 81
2023
Q3 		$1.71M Buy
23,462
+2,195
+10% +$175K 0.06% 80
2023
Q2 		$1.77M Sell
21,267
-955
-4% -$79.9K 0.06% 81
2023
Q1 		$1.69M Buy
22,222
+540
+2% +$44.8K 0.05% 89
2022
Q4 		$1.8M Buy
21,682
+234
+1% +$18.9K 0.07% 87
2022
Q3 		$1.7M Sell
21,448
-1,405
-6% -$118K 0.07% 98
2022
Q2 		$1.7M Sell
22,853
-4,835
-17% -$363K 0.05% 114
2022
Q1 		$2.49M Sell
27,688
-3,193
-10% -$295K 0.07% 102
2021
Q4 		$3.46M Buy
30,881
+3,721
+14% +$449K 0.1% 82
2021
Q3 		$3.41M Buy
27,160
+6,009
+28% +$774K 0.08% 87
2021
Q2 		$2.86M Buy
21,151
+9,495
+81% +$1.25M 0.06% 83
2021
Q1 		$1.58M Buy
11,656
+4,226
+57% +$633K 0.04% 91
2020
Q4 		$1.05M Buy
7,430
+1,142
+18% +$146K 0.03% 96
2020
Q3 		$701K Buy
6,288
+3,426
+120% +$384K 0.02% 97
2020
Q2 		$320K Buy
2,862
+750
+36% +$73.9K 0.01% 99
2020
Q1 		$164K Sell
2,112
-616
-23% -$54.5K 0.01% 113
2019
Q4 		$259K Sell
2,728
-1,279
-32% -$111K 0.02% 98
2019
Q3 		$306K Buy
4,007
+3,947
+6,578% +$328K 0.03% 88
2019
Q2 		$5K Sell
60
-1,333
-96% -$114K ﹤0.01% 114
2019
Q1 		$126K Sell
1,393
-1,282
-48% -$109K 0.01% 91
2018
Q4 		$187K Hold
2,675
– – 0.01% 91
2018
Q3 		$256K Hold
2,675
– – 0.02% 83
2018
Q2 		$255K Buy
2,675
+2,296
+606% +$211K 0.03% 69
2018
Q1 		$33K Buy
+379
New +$34.6K ﹤0.01% 109

Other funds holding XBI

BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Sumitomo Mitsui Financial Group's XBI Position: Q2 2026 in Review

Sumitomo Mitsui Financial Group reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 13% in Q2 2026, selling an estimated $169K and leaving 8,359 shares worth $1.32M. The position accounts for 0.03% of the portfolio, ranked #91.

Sumitomo Mitsui Financial Group first reported a position in XBI in Q1 2018 and has held it in 34 quarters since. The position peaked at $64.4M in Q4 2025. 933 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

  • Sumitomo Mitsui Financial Group held 8,359 shares of State Street SPDR S&P Biotech ETF worth $1.32M as of Q2 2026.
  • Sumitomo Mitsui Financial Group sold 1,249 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $169K.
  • State Street SPDR S&P Biotech ETF made up 0.03% of Sumitomo Mitsui Financial Group's portfolio in Q2 2026, its #91 holding.
  • Sumitomo Mitsui Financial Group first reported a position in State Street SPDR S&P Biotech ETF in Q1 2018 and has held it in 34 quarters since.
  • Sumitomo Mitsui Financial Group's State Street SPDR S&P Biotech ETF position peaked at $64.4M in Q4 2025.
  • 933 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Sumitomo Mitsui Financial Group's 13F filing for Q2 2026, filed 13 Aug 2026.